for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kyowa Kirin Co Ltd

4151.T

Latest Trade

2,394.00JPY

Change

-2.00(-0.08%)

Volume

714,600

Today's Range

2,384.00

 - 

2,411.00

52 Week Range

1,674.00

 - 

2,462.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,396.00
Open
2,390.00
Volume
714,600
3M AVG Volume
26.04
Today's High
2,411.00
Today's Low
2,384.00
52 Week High
2,462.00
52 Week Low
1,674.00
Shares Out (MIL)
536.95
Market Cap (MIL)
1,292,760.00
Forward P/E
22.28
Dividend (Yield %)
1.67

Next Event

Dividend For 4151.T - 20.0000 JPY

Latest Developments

More

Ardelyx And Kyowa Kirin Expand Partnership With Two Additional Agreements

Kyowa Kirin Inc Says Nourianz (Istradefylline) Now Available In U.S. For Treatment Of Parkinson's Disease "Off" Episodes

Ultragenyx And Kyowa Kirin Say U.S. FDA Approves Label Update For Crysvita

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kyowa Kirin Co Ltd

Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of pharmaceuticals and industrial raw materials mainly for amino acid and nucleic acid related substances, as well as healthcare products.

Industry

Biotechnology & Drugs

Contact Info

Otemachi Financial City Grand Cube

1-9-2, Ote-machi

+81.3.52057200

https://www.kyowakirin.co.jp/

Executive Leadership

Nobuo Hanai

Chairman of the Board

Masashi Miyamoto

President, Chief Executive Officer, Representative Director

Yutaka Ohsawa

Executive Vice President, Representative Director

Toshifumi Mikayama

Senior Managing Executive Officer, Director of Overseas Business, Director

Hiroshi Sugitani

Managing Executive Officer, Chief Director of Sales

Key Stats

2.10 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2016

0.3K

2017

0.4K

2018

0.3K

2019(E)

0.3K
EPS (JPY)

2016

34.120

2017

78.380

2018

99.400

2019(E)

107.521
Price To Earnings (TTM)
38.20
Price To Sales (TTM)
4.06
Price To Book (MRQ)
1.95
Price To Cash Flow (TTM)
23.68
Total Debt To Equity (MRQ)
2.76
LT Debt To Equity (MRQ)
2.36
Return on Investment (TTM)
5.07
Return on Equity (TTM)
4.57

Latest News

Latest News

BRIEF-Aevi Genomic Medicine Expands Collaboration With Kyowa Hakko Kirin Co

* AEVI GENOMIC MEDICINE INC - EXPANDED COLLABORATION WITH KYOWA HAKKO KIRIN CO LTD

BRIEF-Kyowa Kirin, Ultragenyx Announce Crysvita Receives Conditional Marketing Authorization In Europe For The Treatment Of X–Linked Hypophosphatemia In Children

* KYOWA KIRIN AND ULTRAGENYX ANNOUNCE CRYSVITA® (BUROSUMAB) RECEIVES CONDITIONAL MARKETING AUTHORIZATION IN EUROPE FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA IN CHILDREN

BRIEF-Kyowa Hakko Kirin appoints KPMG AZSA LLC as new corporate auditor

* Says it appoints KPMG AZSA LLC as new corporate auditor, to replace Ernst & Young ShinNihon LLC, effective March 23

BRIEF- Kyowa Hakko Kirin sells 66.6 pct stake in unit Kyowa Medex

* Says it sold 66.6 percent stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd, on Jan. 4

BRIEF-Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE BUROSUMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA IN CHILDREN

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage:

BRIEF-Kyowa Hakko Kirin Announces FDA Acceptance For Filing And Priority Review Designation Of Mogamulizumab's Biologics License Application

* KYOWA HAKKO KIRIN ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW DESIGNATION OF MOGAMULIZUMAB'S BIOLOGICS LICENSE APPLICATION Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

* Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

BRIEF-Kyowa Hakko Kirin says voluntary adoption of International Financial Reporting Standards (IFRS)

* Says it plans to adopt International Financial Reporting Standards (IFRS) as the new accounting method, to replace the Japanese Generally Accepted Accounting Principles

BRIEF-ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

* ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

BRIEF- Kyowa Hakko Kirin to sell part of stake in unit Kyowa Medex

* Says it will sell a part of stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd.

BRIEF- R&I affirms Kyowa Hakko Kirin's rating at "A+" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

BRIEF-Ultragenyx, Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in U.S.

* Ultragenyx and Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in the U.S.

BRIEF-Sumitomo Chemical buys Kyowa Hakko's agrochemical segment - Nikkei

* Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen

BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab

* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia

BRIEF-Kyowa Hakko Kirin Co Ltd's phase 3 study of mogamulizumab a met its primary endpoint

* Kyowa Hakko Kirin Co Ltd -announced global phase 3 study of mogamulizumab in patients with cutaneous t-cell lymphoma met its primary endpoint

BRIEF-Kyowa Hakko Kirin sets up KYOWA KIRIN FRONTIER Co., Ltd.

Kyowa Hakko Kirin Co Ltd : * Says it set up KYOWA KIRIN FRONTIER Co., Ltd. * Says the capital is 100 million yen Source text in Japanese:https://goo.gl/pbfRNt Further company coverage: (Beijing Headline News)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up